Innovative Therapeutics Greenovation Biotech specializes in developing plant-made next-generation therapeutics, leveraging proprietary BryoTechnology to produce highly-efficient glycoproteins, which can be appealing for collaborations or licensing agreements aimed at rare disease treatments.

Rare Disease Focus With their lead product Moss-aGal targeting Fabry Disease, Greenovation presents opportunities for strategic partnerships in the rare disease space, especially with organizations seeking novel enzyme therapies.

Recent Platform Expansion The launch of their moss-based development platform and ongoing transformation into Eleva indicates a growth in technology capacity, offering potential for scalable bioproduction solutions for pharmaceutical partners.

Growth Potential Although currently generating limited revenue, Greenovation’s innovative platform and focus on next-generation biologics position it as a promising partner for early-stage collaborations seeking cutting-edge biopharmaceutical development.

Strategic Ownership Majority ownership by Zukunftsfonds Heilbronn and L-EigenkapitalAgentur signals strong regional financial backing, providing stability and potential for expansion into new markets or product lines through targeted business development efforts.